October 19, 2006 -- LeMaitre Vascular, a medical device company, completed its IPO today, placing 6 million shares at $7; Array BioPharma reported that its anti-inflammatory drug met Phase I endpoints; Accentia said BiovaxID produced remissions in patients with Non-Hodgkin’s Lymphoma; the FDA expanded the label of allergy drug Allegra from Sanofi-Aventis to include children from 2 to 11 years of age; Centocor said the FDA approved the use of Remicade as a preventative therapy for ulcerative colitis; and Durect reported Voyager Pharma will end the Phase III clinical trial of an Alzheimer’s drug early. The Centient Biotech 200™ was off by 11 points at 3955, a loss of .29%. More details...
